Clarity Receives $6.7 million R&D Tax Incentive Refund
Sydney, Australia 18 April 2023 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that it has received a $6,726,900 Research and Development (R&D) Tax Incentive refund as part of the Australian Federal Government’s…